Making Patients Comfortable from Start to Finish
Oraqix should be discussed with patients prior to their scheduled procedure. Oraqix should not be administered to patients with hypersensitivity to amide type local anesthetics.
Click the video icon to see the appropriate way to discuss Oraqix with your patients and determine their eligibility for its use and watch "Clinical Application of Oraqix in an Enhanced Therapeutic Approach to Nonsurgical Therapy by Casey Hein, RHD, MBA."
Following SRP treatment with Oraqix in 391 patients, the most frequent adverse events were local reactions in the oral cavity. These events, which occurred in approximately 15% of patients, included pain, soreness, irritation, numbness, vesicles, ulcerations, edema and/or redness in the treated area. Of the 391 patients treated with Oraqix, five developed ulcerative lesions and two developed vesicles of mild to moderate severity near the site of SRP. In addition, ulcerative lesions in or near the treated area were also reported for three out of 168 patients who received placebo. Other symptoms reported in more than one patient were headache, taste perversion, nausea, fatigue, flu, respiratory infection, musculoskeletal pain and accident/injury.